ADVFN ADVFN

Hot Features

Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
Nxera Pharma Company Ltd (PK)

Nxera Pharma Company Ltd (PK) (SOLTF)

6,00
-0,37
(-5,81%)
Fermé 03 Juillet 10:00PM

Nxera Pharma Company Ltd (PK) (SOLTF) Action

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Statistiques et détails clés

Dernier
6,00
( -5,81% )
Prix Achat
5,35
Prix Vente
6,54
Volume échangé
1 150
6,00 Fourchette du Jour 6,00
4,90 Plage de 52 semaines 7,94
Cap du marché
Clôture Veille
6,37
Ouverture
6,00
Dernière Transaction
1150
@
6
Dernière heure de transaction
Volume financier
US$ 6 900
VWAP
6,00
Volume moyen (3 m)
US$ 1 058 156
Actions en circulation
92 612 178
Rendement du Dividende (LTM)
Ratio Cours sur Bénéfices
-8,97
Bénéfice par action (BPA)
-110,34
Chiffre d'affairess (LTM)
34,23B
Bénéfice net (LTM)
-9,98B

À propos de Nxera Pharma Company Ltd (PK)

Nxera Pharma Co., Ltd. operates as a biopharmaceutical company, engages in drug discovery and development in Japan, the United States, Germany, Switzerland, Bermuda, the United Kingdom, and internationally. The company offers NxWave, a GPCR-targeted structure-based drug discovery platform; PIVLAZ fo... Nxera Pharma Co., Ltd. operates as a biopharmaceutical company, engages in drug discovery and development in Japan, the United States, Germany, Switzerland, Bermuda, the United Kingdom, and internationally. The company offers NxWave, a GPCR-targeted structure-based drug discovery platform; PIVLAZ for the cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aSAH; and QUVIVIQ for insomnia. It develops NBI-1117568, an muscarinic M4 agonist in phase 3 trial for schizophrenia, dementia and other neuropsychiatric disorders; ORX750, an OX2 agonist for narcolepsy, idiopathic hypersomnia, and other sleep-wake disorders; NBI-1117570, a dual muscarinic M1/M4 agonist; and HTL0039732, an EP4 antagonist immunotherapy drug. The company’s products in phase 1 trial include PF-07054894, a CCR6 antagonist and NXE0033744, an EP4 agonist for inflammatory bowel disease; PF-07258669, a MC4 antagonist for anorexia; NBI-1117569, a muscarinic M4-preferring agonist, and NBI-1117567, a muscarinic M1 agonist for major central nervous system disorders; TMP-301, a mGlu5 NAM for substance use disorders; and NXE0048149, a GPR52 agonist for schizophrenia. Its products in preclinical trial comprise KY1051, a CXCR4 mAb for immuno-oncology; and NXE0027477, a GPR35 agonist for inflammatory bowel disease and GI disorders. The company also develops other discovery-stage drugs. It has strategic collaborations with Tempero Bio, Pharmenable Therapeutics, Antiverse, Sanofi, Cancer Research UK, Centessa Pharmaceuticals, Lilly, AbbVie, Genentech, Pfizer, Neurocrine Biosciences, Antiverse, and Novartis International AG. The company was formerly known as Sosei Group Corporation. Nxera Pharma Co., Ltd. was incorporated in 1990 and is headquartered in Minato, Japan. Show more

Secteur
Healthcare
Industrie
Biotechnology & Life Sciences
Site Web
Siège social
Minato, Japan
Fondé
1990
Nxera Pharma Company Ltd (PK) est coté dans le secteur Healthcare de la OTC Markets avec le ticker SOLTF. Le dernier cours de clôture d'Nxera Pharma (PK) était de US$6,37. Au cours de la dernière année, les actions de Nxera Pharma (PK) ont été négociées dans une fourchette de prix de US$ 4,90 à US$ 7,94.

Nxera Pharma (PK) compte actuellement 92 612 178 actions en circulation. La capitalisation boursière d'Nxera Pharma (PK) est de US$555,67 million. Nxera Pharma (PK) a un ratio cours/bénéfice (ratio PE) de -8.97.
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10006000CS
4-0.185-2.991107518196.1856.3765006.2035CS
12-0.53-8.116385911186.537.945.5161876.4066779CS
260.8115.60693641625.197.945.1543026.38407472CS
52-0.2-3.225806451616.27.944.919136.31136843CS
156-4.38-42.196531791910.3813.524.912828.55212333CS
260-10.3203-63.23596992716.320322.7824.9144411.29736742CS

SOLTF - Frequently Asked Questions (FAQ)

What is the current Nxera Pharma Company Ltd (PK) share price?
The current share price of Nxera Pharma Company Ltd (PK) is US$ 6,00
How many Nxera Pharma Company Ltd (PK) shares are in issue?
Nxera Pharma Company Ltd (PK) has 92 612 178 shares in issue
What is the market cap of Nxera Pharma Company Ltd (PK)?
The market capitalisation of Nxera Pharma Company Ltd (PK) is USD 555,67M
What is the 1 year trading range for Nxera Pharma Company Ltd (PK) share price?
Nxera Pharma Company Ltd (PK) has traded in the range of US$ 4,90 to US$ 7,94 during the past year
What is the PE ratio of Nxera Pharma Company Ltd (PK)?
The price to earnings ratio of Nxera Pharma Company Ltd (PK) is -8,97
What is the cash to sales ratio of Nxera Pharma Company Ltd (PK)?
The cash to sales ratio of Nxera Pharma Company Ltd (PK) is 2,68
What is the registered address of Nxera Pharma Company Ltd (PK)?
The registered address for Nxera Pharma Company Ltd (PK) is Midtown East, Minato, Tokyo, 107-0052
What is the Nxera Pharma Company Ltd (PK) website address?
The website address for Nxera Pharma Company Ltd (PK) is www.nxera.life
Which industry sector does Nxera Pharma Company Ltd (PK) operate in?
Nxera Pharma Company Ltd (PK) operates in the Biotechnology & Life Sciences sector

SOLTF Transactions

Plus

Transactions différées

Pour obtenir des transactions en temps réel, améliorez votre compte

Passer à la version en temps réel
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock